Ingevity (NGVT) Dropped, So What Is Drawing Attention Now?
Ingevity (NGVT) recently received recognition from TIME as one of America's Best Companies for 2026, yet its stock has pulled back recently despite strong longer-term returns. While one narrative suggests the stock is 16.9% undervalued at $89 based on future cash generation and portfolio repositioning, another view highlights its high current P/E ratio of 100.9x, significantly above industry averages, suggesting potential overvaluation based on today's earnings. Investors are encouraged to weigh the optimistic and concerning factors and conduct their own due diligence.
Ingevity Corp (NGVT) President & CEO David Li Sells 10,092 Shares
Ingevity Corp's President & CEO, David Li, sold 10,092 shares of NGVT stock for approximately $764,671, continuing a pattern of insider selling over the past year with no insider purchases. The stock is currently trading at $75.77, which GuruFocus assesses as significantly overvalued with a price-to-GF-Value ratio of 1.64. This insider activity and valuation assessment suggest caution for investors.
Ingevity CEO David H. Li sells USD 765,877.32 in common shares
Ingevity President and CEO David H. Li sold 10,092 common shares between August 14-18, at weighted-average prices ranging from $74.71 to $75.83, totaling approximately $765,877.32. Following these transactions, Li retained 120,544 common shares. The information is based on an EDGAR filing by Ingevity Corporation.
Ingevity (NGVT) CEO sells 10,092 shares around $75 in August sales
Ingevity Corp's President & CEO, David H. Li, sold a total of 10,092 shares of company common stock in three open-market transactions between August 14 and August 18, 2026. These sales were executed under a Rule 10b5-1 trading plan, with weighted average prices ranging from $74.71 to $75.83 per share, totaling approximately $765,000. Following these transactions, Li directly holds 120,544 shares of Ingevity common stock.
Ingevity included in TIME America’s Best Companies 2026 list
Ingevity Corporation has been recognized on TIME's list of America's Best Companies 2026, an award presented in collaboration with Statista. The recognition is based on employee satisfaction, financial performance, sustainability, and transparency. Ingevity, a global specialty materials company, emphasizes that this achievement reflects the dedication and commitment of its 1,400 employees.
Ingevity (NGVT) Stock Looks Stretched On High Earnings Expectations
Ingevity (NGVT) stock has seen an 81.0% return over the past year, but its current P/E ratio of 100.9x is significantly higher than the industry average, suggesting it may be overvalued. While strong execution could justify this premium, any disappointment in earnings or balance sheet health could lead to a multiple reset. The valuation indicates that the market has high confidence in Ingevity's future performance.
Asphalt Emulsifiers Market
The global asphalt emulsifiers market is projected to grow from USD 2.1 billion in 2026 to USD 3.6 billion by 2036, exhibiting a CAGR of 5.4%. This growth is primarily driven by recurring pavement preservation and resurfacing programs worldwide, with cationic emulsifiers expected to dominate the market share. Key players like Nouryon and Arkema focus on providing comprehensive formulation support and local availability alongside their chemical products to meet specific regional requirements and application needs.
Ingevity Corp (NGVT) President & CEO David Li Sells 10,000 Shares
Ingevity Corp's President & CEO, David Li, sold 10,000 shares of NGVT stock for approximately $761,800. This sale contributes to a bearish trend in insider activity, with no insider buys in the past year, and aligns with the company's "Significantly Overvalued" GF Value of $46.16 against its trading price of $76.18. This suggests a cautious outlook for current and prospective shareholders due to stretched valuation multiples.
Ingevity (NYSE:NGVT) CEO Sells $383,100.00 in Stock
Ingevity CEO David Li sold 5,000 shares of company stock for $383,100, reducing his total holdings by 3.56%. The sale was part of a pre-arranged Rule 10b5-1 trading plan. Ingevity recently reported strong quarterly earnings, beating analyst expectations, and analysts currently have a "Hold" rating on the stock with an $80 price target.
Ingevity CEO David Li sells $761,750 in stock
Ingevity CEO David Li sold $761,750 worth of company common stock in two transactions on August 12 and 13, 2026, disposing of 5,000 shares each day. The sales occurred as Ingevity stock trades near its 52-week high, having delivered significant year-to-date and annual returns. Despite the stock appearing overvalued according to InvestingPro, the company recently surpassed Q2 analyst expectations with strong adjusted earnings and revenue.
Ingevity CEO David Li sells $761,750 in stock By Investing.com
Ingevity CEO David Li sold a total of $761,750 worth of company stock through two separate transactions in mid-August. These sales occurred while Ingevity's stock was near its 52-week high, having delivered strong year-to-date and annual returns. Despite the sales, Li still directly owns 130,636 shares, and the company recently surpassed Q2 earnings and revenue expectations.
Ingevity (NGVT) CEO David Li sells 10,000 shares under 10b5-1 plan
Ingevity Corp's President & CEO, David H. Li, sold a total of 10,000 shares of company common stock in two open-market transactions on August 12 and August 13, 2026, under a Rule 10b5-1 trading plan. The sales were executed at weighted average prices of $76.62 and $75.73 per share, respectively, totaling approximately $762,000. Following these transactions, Li directly holds 130,636 shares of common stock.
Ingevity (NYSE:NGVT) Is Posting Promising Earnings But The Good News Doesn’t Stop There
Ingevity Corporation's recent earnings report, despite a seemingly unchanged stock price, reveals encouraging underlying numbers. The company boasts a negative accrual ratio, indicating its free cash flow significantly exceeds statutory profit, a positive sign for investors. Additionally, unusual items reduced reported profits, suggesting that Ingevity's actual earnings potential may be stronger than initially perceived.
Ingevity Corp SEC Filing (Aug 12, 2026)
Ingevity Corp filed a Form 144 SEC document on August 12, 2026, indicating a proposed sale of securities. The filing details the sale of 20,092 common shares with an aggregate market value of $1,562,956.68 through Morgan Stanley Smith Barney LLC, acquired on April 7, 2026, as Restricted Stock Units.
Does Profitability Swing And Buybacks Shift The Bull Case For Ingevity (NGVT)?
Ingevity Corporation reported a swing to profitability in Q2 2026, with sales of US$314.1 million and net income of US$35.3 million, along with a significant share repurchase program. This financial improvement, coupled with higher full-year guidance, supports the company's strategy of focusing on higher-value businesses and returning cash to shareholders. While this progress strengthens the near-term investment narrative, potential risks from cyclical demand and tariff exposure in certain segments remain.
Ingevity (NGVT) Q2 2026 Earnings Call Transcript
Ingevity (NGVT) reported strong Q2 2026 financial results, with adjusted EBITDA up 14% and adjusted EPS reaching $1.74, driven by a shift towards higher-value carbon solutions for hybrid vehicles and disciplined operational execution. The company raised its full-year EBITDA and EPS guidance, reflecting confidence in its strategic portfolio transformation and ongoing share repurchase program. Management highlighted a significant win in the PFAS filtration market, indicating new growth opportunities for its advanced carbon technologies.
Ingevity Corporation (NGVT) Stock Forecasts
Argus has issued a report on Ingevity Corporation (NGVT), a U.S.-based chemical manufacturer with segments in Performance Chemicals, Advanced Polymer Technologies, and Performance Materials. The firm has raised its target price for NGVT to $79.00 from its current price of $77.82, indicating a positive outlook for the stock.
Ingevity (NGVT) Q2 2026 Earnings Call Transcript
Ingevity (NGVT) reported strong Q2 2026 results, with adjusted EBITDA up 14% and margins expanding, driven by a shift to hybrid vehicles benefiting their carbon business. The company raised its full-year guidance for adjusted EBITDA and EPS, and is progressing with portfolio simplification, including the advanced stage sale of Advanced Polymer Technologies. Despite some headwinds from higher asphalt prices and anticipated weaker auto production in H2, Ingevity is confident in its strategic execution and organic growth opportunities like PFAS filtration.
Ingevity (NYSE:NGVT) Is Posting Promising Earnings But The Good News Doesn’t Stop There
Ingevity Corporation's recent earnings report, while seemingly unremarkable for its stock price, reveals encouraging underlying factors. The company exhibits a negative accrual ratio of -0.11, indicating its free cash flow significantly exceeded its statutory profit, with US$155m in FCF against US$25.2m in profit. This strong cash conversion is partly due to US$174m in unusual items that reduced reported profit but are considered one-off in nature, suggesting that Ingevity's statutory profit likely understates its true earnings potential.
Ingevity Corp (NGVT) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Ingevity Corp (NGVT), detailing its current earnings forecast score, average price target, and analyst ratings. It highlights that the company ranks 3 out of 65 in the Chemicals industry with a "Buy" trend based on analyst opinions. Key financial estimates for EPS and revenue are also presented, along with a peer comparison.
Cleaner Water, Reduced Emissions Feature in Ingevity Report
Ingevity Corporation has released its 2025 Sustainability Report, "A Decade of Performance, a Future of Possibility," highlighting how its advanced materials and technologies contribute to environmental goals such as reduced emissions, extended infrastructure life, cleaner water, and the use of renewable raw materials. The report details the company's commitment to creating value for customers and stakeholders by purifying, protecting, and enhancing the world. It also outlines efforts to support a global vision for a more sustainable world, adhering to Global Reporting Initiative (GRI) and Sustainability Accounting Standards Board (SASB) standards.
Ingevity Releases 2025 Sustainability Report, Highlights Performance and Impact
Ingevity Corporation has released its 2025 Sustainability Report, titled "A Decade of Performance, a Future of Possibility," which details how its advanced materials and technologies help customers achieve environmental goals. The report highlights the company's commitment to sustainability through products that reduce emissions, extend infrastructure life, support cleaner water, and incorporate renewable raw materials. Ingevity aims to create long-term value for stakeholders by purifying, protecting, and enhancing the world.
Ingevity (NYSE: NGVT) legal chief Ryan Fisher sells 2,709 shares
Ingevity's SVP, General Counsel & Secretary, Ryan C. Fisher, sold a total of 2,709 shares of company common stock on August 3, 2026. The sales were conducted in two separate open market transactions at prices of $73.76 and $73.67 per share, totaling approximately $200,000. These transactions were not executed under a Rule 10b5-1 trading plan.
Ingevity Corp SEC Filing (Aug 3, 2026)
This article reports on an Ingevity Corp (NGVT) SEC Form 144 filing from August 3, 2026. The filing indicates a proposed sale of 2,709 shares of common stock by an unnamed person, acquired through restricted stock on February 18, 2021, with an aggregate market value of $199,703.80. The sale is to be executed through Morgan Stanley Smith Barney LLC on the NYSE.
Is Ingevity (NGVT) Cheap On Earnings And Its Completed Buyback?
Ingevity (NGVT) recently reported Q2 2026 results, showing improved profitability compared to the previous year, despite lower sales, and announced the completion of a multi-year share repurchase program. While the company's share price has seen significant gains year-to-date and over the last year, its valuation, with a P/E ratio of 100.9x, is considerably higher than industry averages, presenting potential valuation risk if future growth falls short of ambitious analyst expectations. Analysts project a fair value of $89 per share, suggesting the stock is undervalued, but this hinges on significant profit margin increases and specific assumptions about future cash flows.
Ingevity Corp (NGVT) Shares Surge 4.2% -- What GF Score of 62 Te
Ingevity Corp (NGVT) shares surged 4.2% to $73.11, but GuruFocus's GF Value™ indicates the stock is significantly overvalued by 59.0% compared to its estimated intrinsic value of $45.99. Despite a GF Score™ of 62/100, highlighting strong profitability and momentum, the company faces challenges in financial strength and growth. Investors are advised to exercise caution due to the overvaluation and mixed signals from institutional investors and a lack of insider activity.
Ingevity Corp (NGVT) Shares Surge 4.2% -- What GF Score of 62 Tells Investors
Ingevity Corp (NGVT) shares surged 4.2% to $73.11, despite a GuruFocus (GF) Score of 62/100 indicating above-average performance but also weaknesses. The stock is considered significantly overvalued with its current price being 59.0% above the GF Value estimate, and its P/E ratio of 49.7x is much higher than its historical median. Mixed activity from institutional investors and an absence of insider trading suggest caution is warranted.
Ingevity Corp 2Q 2026: Revenue $314.1M, Net income $35.3M, EPS $1— 10-Q Summary
Ingevity Corp reported its second-quarter 2026 results, showing revenue of $314.1M, net income of $35.3M, and diluted EPS of $1. This represents a significant improvement compared to the prior-year quarter's net loss and diluted loss per share. The company's net sales declined by about 5% year-over-year, primarily due to divestitures, although Performance Materials and APT segments showed growth and improved pricing.
Ingevity reports second quarter 2026 financial results
Ingevity reported strong financial results for the second quarter of 2026, with net sales of $314.1 million and adjusted EBITDA of $115.0 million, leading the company to raise its full-year guidance. The performance was driven by growth across its Performance Materials, Pavement Technologies (excluding Road Markings), and Advanced Polymer Technologies segments, alongside the successful divestiture of its Road Markings product line. The company plans to use its strong free cash flow to reduce leverage and return cash to shareholders, focusing on differentiated carbon technologies and organic growth opportunities.
Ingevity Corporation 2026 Q2 - Results - Earnings Call Presentation (NYSE:NGVT) 2026-07-30
Ingevity Corporation (NGVT) has published its Q2 2026 earnings call presentation. The company reported an EPS of $1.74, beating estimates by $0.41, and revenue of $314.10M, surpassing expectations by $1.90M despite a 13.97% year-over-year decrease. This information is provided by Seeking Alpha's transcripts team.
Ingevity Corp (NGVT) Risk Assessment: Volatility, Financial Risk & Investment Risk
This article provides a risk assessment for Ingevity Corp (NGVT), detailing its current risk score of 6.25, which ranks 31 out of 65 in the Chemicals industry. It examines key metrics such as beta, VaR, maximum drawdown, and various volatility measures, indicating the stock's tendency for higher returns in upward markets and greater declines in downward markets. The assessment also includes Sharpe Ratios and liquidity indicators.
Earnings Flash (NGVT) Ingevity Corporation Posts Q2 Adjusted EPS $1.74 per Share, Vs. FactSet Est of $1.33
Ingevity Corporation (NGVT) reported strong Q2 adjusted earnings per share of $1.74, significantly surpassing the FactSet estimate of $1.33. This indicates a positive performance for the company during the second quarter.
Ingevity (NGVT) Tops Q2 Earnings and Revenue Estimates
Ingevity (NGVT) reported strong Q2 earnings of $1.74 per share, significantly surpassing the Zacks Consensus Estimate of $1.31, and revenues of $314.1 million, beating estimates by 4.91%. Though the company has outperformed the market year-to-date, its current Zacks Rank #3 (Hold) suggests it will perform in line with the market in the near future. Investors are advised to monitor changes in earnings estimates for future performance insights.
Ingevity: Q2 Earnings Snapshot
This article provides a brief snapshot of Ingevity's second-quarter earnings. Due to the limited content, specific financial details are not available.
Ingevity Corporation (NYSE: NGVT) boosts 2026 EBITDA and free cash flow outlook
Ingevity Corporation reported strong second-quarter 2
Ingevity Corp (NGVT) Q2 2026 Earnings
Ingevity Corp (NGVT) reported its Q2 2026 earnings, significantly beating analyst expectations with an EPS of $1.74 against an estimated $1.33, representing a 31.2% beat. Revenue reached $314 million, slightly above the $312 million estimate. This strong performance was attributed to high demand for activated carbon and supply disruptions faced by competitors in specialty polymers, leading management to raise full-year adjusted EPS guidance to $5.00-$5.45.
Ingevity earnings up next as specialty chemicals maker eyes rebound
Ingevity Corp. is set to announce its second-quarter earnings, with analysts expecting improved sequential performance but a year-over-year decline. Investors will be observing whether the company can reverse its revenue decline, sustain momentum in its various segments, and maintain strong margin performance amid changing market dynamics. The previous quarter showed mixed results, with earnings beating estimates but revenue falling short.
Form 4 Ingevity Corp For: 29 July By Investing.com
This article from Investing.com announces a Form 4 filing for Ingevity Corp on July 29. The content provided is minimal, simply stating the filing's existence and linking to Ingevity Corp's stock symbol (NGVT). No details about the Form 4's contents are provided within the article itself.
Ingevity Corp (NGVT) Valuation: PE, PB & Fair Value Analysis
Ingevity Corp (NGVT) has a current valuation score of 8.94, placing it 14th out of 65 companies in the Chemicals industry. The company's P/E ratio is -21.40, which is significantly below its recent high and above its recent low. Key valuation metrics like P/B, P/S, and P/CF have not yet been disclosed by the company.
Ingevity Corp (NYSE: NGVT) CFO reports tax-related share withholding
Ingevity Corp's Senior Vice President and CFO, Phillip John Platt, had 3,294 shares of common stock withheld by the company on July 24, 2026. This action was taken to cover tax withholding obligations related to vested restricted stock units, with an implied price of $73.26 per share. Following this transaction, Platt directly holds 28,339 shares of Ingevity common stock.
Ingevity Corp (NGVT) Institutional Confidence
Ingevity Corp (NGVT) has a strong institutional confidence score of 10.00, placing it first in the Chemicals industry. Institutional shareholding increased by 12.55% quarter-over-quarter, reaching 120.12%, with Chuck Royce being the largest individual institutional shareholder. The article lists the top institutional shareholders and their recent activity.
Ingevity Corporation Revenue Breakdown – SWB:IGX
Ingevity Corporation (SWB:IGX) generated 994.12 million EUR in revenue last year. The Performance Materials segment was the top performer, contributing 516.73 million EUR, while the United States was the largest regional contributor with 498.08 million EUR.
Ingevity Market Sentiment
This article provides an overview of Ingevity (NGVT) market sentiment, focusing on analyst consensus, short interest, options flow, and insider activity. The consensus among five analysts is "Outperform," with an average price target of $63. The short interest is noted at 4.6% and rising, indicating a bearish sentiment from short-sellers.
Ingevity Corp (NGVT) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Ingevity Corp's (NGVT) stock information
Ingevity Corp (NGVT) Cash Flow
This article provides a detailed cash flow statement for Ingevity Corp (NGVT), presenting both quarterly and annual data for operating, investing, and financing activities. It includes key financial metrics like operating cash flow, capital expenditures, and free cash flow, alongside their year-over-year changes. The document also offers FAQs defining these cash flow types and their significance for investors.
Ingevity Corp (NGVT) Financial Health: Profitability & Balance Sheet Analysis
This article provides a financial health analysis of Ingevity Corp (NGVT), ranking its financial status as stable with average operating efficiency within the Chemicals industry. The company's financial score is 7.13, placing it 35th out of 65. Although its latest quarterly revenue decreased by 9.15% and net profit by 191.71% year-over-year, the analysis includes scores for Quality of Earnings, Operational Efficiency, Growth Potential, and Shareholder Returns.
Ingevity (NGVT) Stock May Be Above Fair Value Following Germany Approval
Ingevity (NGVT) stock has seen a 61.9% return over the past year, but its current valuation suggests it may be overvalued, trading at a premium to industry averages on a P/S basis. While the approval of Evotherm P35 in Germany is positive, the stock's future hinges on its ability to sustain demand in higher-value applications and deliver on its product pipeline to justify its revenue multiple. Simply Wall St's analysis indicates the stock is currently not clearly cheap.
How Ingevity Corporation (NGVT) Affects Rotational Strategy Timing
This article analyzes Ingevity Corporation (NGVT) using AI models to provide trading strategies. It highlights a strong near-term sentiment with a positive long-term bias, noting support testing and an exceptional 34.1:1 risk-reward setup. Three distinct strategies—Position Trading, Momentum Breakout, and Risk Hedging—are outlined with specific entry, target, and stop-loss zones.
Is BASt’s Nod to Evotherm P35 Reframing Ingevity (NGVT)’s European Sustainability Edge?
Ingevity Corporation's Evotherm P35 warm-mix additive has received approval from Germany’s Federal Highway Research Institute (BASt), validating its durability and performance under stringent European standards. This approval enhances Ingevity's Pavement Technologies segment, reinforcing its sustainability and technical credibility, though the company still faces challenges in Advanced Polymer Technologies and needs to manage debt and cyclical markets. The investment narrative projects revenue decline but significant earnings growth by 2029, with a fair value estimate significantly higher than its current price.
Brown Advisory Small-Cap Fundamental Value Fund's Ingevity Corp(NGVT) Holding History
This article details Brown Advisory Small-Cap Fundamental Value Fund's historical holdings in Ingevity Corp (NGVT). As of December 31, 2025, the fund held 508,852 shares valued at $30.11 million, representing 2.8% of its portfolio and a 1.42% stake in NGVT. The fund has made 11 purchases and 8 sales of NGVT shares since its initial trade in Q2 2021, resulting in an estimated gain of $712,304.81.
